knowledge -WSS

knowledge

author：hotspot 2025-08-29 19:58:45 - browse：27251

Blood samples — Marion Berard/AFP/GettyImages

With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush.

Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

“There’s going to be capacity issues because there’s just not enough neurologists in the world to treat this pool of patients with Alzheimer’s disease at the moment,” said Mark Stearman, a senior international product manager at Roche focusing on Alzheimer’s diagnostics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Even great ERs can’t make up for American health disparities

explore

WSS

Vertex non

FDA drug safety: Singulair case shows systemic surveillance flaws

Novo Nordisk to expand supply of Wegovy for U.S. patients

Kaiser Permanente unions announce official strike date

Covid vaccines: Private market messier than government rollout

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Wikipedia

knowledge

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Address the ethical violations that led to 'Three Identical Strangers'

Activists slam private health insurers over coverage restrictions

Biden administration opens offers in Medicare drug price negotiations

Sports medicine is finally prioritizing gender equality

Inequities make cancer less preventable for women: report

Medical records are filled with copy

Address the ethical violations that led to 'Three Identical Strangers'

Activists slam private health insurers over coverage restrictions

Cognito secures funding to test medical device for Alzheimer's

entertainment

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Covid vaccines: Private market messier than government rollout

Do digital therapeutics have a future in medicine?

Covid misinformation case heads to Supreme Court

Data show record exodus of life scientists from academia

Menendez indictment could see pharma lose a key ally

focus

entertainment

explore

entertainment